London's SheMed, a rapidly growing women's health technology company, has secured a significant €43 million investment to accelerate its UK expansion and deepen its commitment to personalised, data-driven healthcare solutions. This substantial funding underscores the increasing investor interest in femtech platforms that successfully combine digital innovation with specialised clinical support for women's unique health needs.
Digital Innovation Meets Specialised Care
Established in April 2024 by sisters Olivia and Chloe Ferro, SheMed has quickly become a leader in digital women's health. The platform delivers individualised care pathways, integrating medical oversight, wellness tracking, and dedicated clinician support through a digital interface. Its core offering allows members to track progress, connect with clinicians, and access customised health plans. SheMed's established services include GLP-1 based weight management programmes, which combine medication oversight with lifestyle and wellness coaching to support women with metabolic health concerns.
Strategic Allocation of Major Investment
The €43 million investment, one of the largest recent raises for a UK-headquartered women's health company, will be strategically allocated to several key priorities. These include scaling UK operations with a significant expansion of the workforce, particularly hiring more clinicians and technology engineers. Capital will also be used for technology and data enhancement to refine data-driven tools and improve the user experience. Furthermore, investment will strengthen the clinical infrastructure to support clinical workflows, research initiatives, and the development of new service lines. The firm has already reported rapid growth, serving tens of thousands of women within its first year, confirming a major unmet demand for its services.
Driving Gender-Specific Clinical Research
Beyond clinical service, SheMed is positioning itself as a research-driven platform. Later in 2026, the company plans to publish results from what it describes as the first female-focused GLP-1 clinical study. This research will specifically examine the effects of GLP-1 medications on women’s hormonal and metabolic responses. The study aims to refine treatment pathways and offer valuable, gender-specific insights, addressing a historical limitation in clinical evidence.
Highlighting Sector Growth and Future Outlook
SheMed's successful funding round highlights growing investor confidence in women's health as a high-growth, high-impact segment of the healthcare market. The investment is part of a broader surge in funding for platforms specialising in personalised and preventive care across the UK and Europe, aligning with broader UK health policy shifts that embrace prevention and digital engagement. While the growth is promising, the sector must continue to address challenges related to clinical efficacy, regulatory compliance, data security, and overcoming historical funding barriers faced by female-founded startups. SheMed's €43 million raise is seen as a major signpost for the evolution of women’s health in the UK HealthTech landscape. By combining clinical expertise, data intelligence, and a woman-centred approach, the company is poised to continue leading a sector set for sustained growth.
